Prognostic Significance of a Model Based on Acetaldehyde Dehydrogenase 2 Genetic Polymorphisms in Laryngeal Carcinoma

Abstract

AbstractObjectiveBecause of the high costs associated with early‐stage laryngeal carcinoma diagnosis and prognosis prediction, this study attempts to find valuable targets to establish a novel predictive model by focusing on the aldehyde dehydrogenase 2 (ALDH2) genotype and other peripheral blood markers.Study DesignRetrospective study.SettingTertiary comprehensive hospital.MethodsFrom January 2011 to January 2021, 362 cases of laryngeal carcinoma were included and divided into 2 groups in this retrospective analysis. Information on medical history, alcohol, and tobacco consumption habits, ALDH2 genotypes, and other peripheral blood markers was collected. Endpoints of the current study included disease‐free survival and overall survival. A nomogram model for overall survival was established and evaluated using receiver operating characteristic (ROC) curves.ResultsA total of 236 patients were included in the training cohort, and the other 126 were included in the validation cohort. The median follow‐up of the patients was 9.6 years (interquartile range: 7.5‐12.5 years). Peripheral fibrinogen, hemoglobin, and ALDH2 genotypes were significantly associated with an increase in laryngeal carcinoma mortality rate on Kaplan‐Meier curves. The ROC curve showed that the effectiveness of overall survival prediction by the nomogram model was better than that of traditional clinical staging.ConclusionA prognostic nomogram of laryngeal carcinoma patients involving ALDH2 and peripheral blood markers and T and N stages was constructed and validated.